Fueling fibrosis: BCAT1 links branched-chain amino acid metabolism to collagen production
View Full Paper
Ask AI
Bookmark
Share
Key result
BCAT1 enhances collagen production in activated cardiac fibroblasts by coupling mechanical and TGF-β signaling to a proline biosynthesis program, highlighting it as a therapeutic target for fibrosis.
Figures
Why the study?
Does BCAT1 inhibition reduce cardiac fibrosis and improve contractility in a mouse model of myocardial infarction?
Key Points
- To determine the metabolic mechanisms that sustain extracellular matrix and collagen production during fibroblast activation, focusing on the role of BCAT1 in cardiac fibrosis.
- Analyzed mouse myocardial infarction (MI) models and a suspension culture system of myofibroblasts isolated 3 days post-MI to track transcriptomic shifts across 286 metabolism-related genes.
- Corroborated experimental findings using human clinical transcriptomic datasets from patients with heart failure with preserved ejection fraction, HFrEF (GSE161472), and MASH (GSE126848).
- Bcat1 was identified as one of only five metabolism-related genes significantly upregulated during the early phase after MI, marking early fibroblast activation prior to maximal α-SMA (Acta2) expression.
- BCAT1 activity stimulated HDAC5 phosphorylation at Ser488 and activated SMAD3 to drive the transcription of proline metabolic enzymes ALDH18A1, PYCR1, and EPRS, enhancing collagen I and III synthesis.
- Genetic Bcat1 deficiency or ERG240 treatment suppressed proline enzyme expression, attenuated SMAD3 activation, reduced collagen deposition, and preserved cardiac contractility 28 days after MI.
Structured PICO
Does BCAT1 inhibition reduce cardiac fibrosis and improve contractility in a mouse model of myocardial infarction?
P
Population
Mouse myocardial infarction (MI) model of cardiac fibrosis, and human datasets of heart failure with reduced ejection fraction (HFrEF; GEO GSE161472) and metabolic dysfunction-associated steatohepatitis (MASH; GSE126848).
I
Intervention
Genetic deletion of Bcat1 or pharmacological inhibition of BCAT1 using the small molecule ERG240 (initiated immediately or 7 days after MI).
C
Comparator
Control animals.
O
Outcome
Cardiac fibrosis and contractility at 28 days after MI.surrogate
Limitations
- Lineage-specific approaches are required to define the relative contribution of fibroblasts compared with other BCAT1-expressing cell populations.
- The therapeutic window within which BCAT1 inhibition can safely suppress pathological remodeling without impairing wound healing is unknown.
- Whether this mechanism extends to pulmonary fibrosis, chronic kidney disease, systemic sclerosis, or other fibrotic disorders remains to be determined.
- Relied primarily on global BCAT1 inhibition rather than lineage-specific approaches
- Therapeutic window for safe suppression of pathological remodeling without impairing wound healing is unknown
- Unclear if mechanism extends to other fibrotic disorders like pulmonary fibrosis or chronic kidney disease
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Fibrosis remains a major driver of organ dysfunction, yet the metabolic programs that sustain extracellular matrix production are incompletely understood. In this issue of the JCI, Takizawa and colleagues identified branched-chain amino acid transaminase 1 (BCAT1) as a crucial metabolic regulator of fibroblast activation and fibrosis in a model of cardiac fibrosis. These findings place branched-chain amino acid metabolism as a pivotal contributor to fibroblast activation and highlight BCAT1 as a promising therapeutic target for fibrotic disease.”
“Their work positions BCAT1 at the intersection of BCAA metabolism and profibrotic signaling, revealing a mechanism through which fibroblasts acquire the metabolic capacity necessary to sustain collagen synthesis and tissue fibrosis. Interestingly, these findings are consistent with our group's previous work identifying glutamine and glutamate as key metabolic determinants of fibroblast activation and differentiation, further supporting a central role for amino acid metabolism in fibrogenesis. One of the most intriguing findings of the study by Takizawa et al. is the identification of BCAT1 as an early marker of fibroblast activation.”
Implication
BCAT1 is a crucial metabolic regulator of fibroblast activation, and its inhibition represents a promising therapeutic target for reducing pathological cardiac fibrosis after myocardial infarction.
Abstract
Fibrosis remains a major driver of organ dysfunction, yet the metabolic programs that sustain extracellular matrix production are incompletely understood. In this issue of the JCI , Takizawa and colleagues identified branched-chain amino acid transaminase 1 (BCAT1) as a crucial metabolic regulator of fibroblast activation and fibrosis in a model of cardiac fibrosis. Their observations were corroborated by analyses of datasets from patients with heart failure with preserved ejection fraction and metabolic dysfunction–associated steatohepatitis. They report that by coupling mechanical and TGF-β signaling to a proline biosynthesis and utilization program, BCAT1 enhanced collagen production in activated cardiac fibroblasts. These findings place branched-chain amino acid metabolism as a pivotal contributor to fibroblast activation and highlight BCAT1 as a promising therapeutic target for fibrotic disease.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Ronfini et al. (2026) conducted an editorial in Fibrosis. BCAT1 inhibition was evaluated. BCAT1 enhances collagen production in activated cardiac fibroblasts by coupling mechanical and TGF-β signaling to a proline biosynthesis program, highlighting it as a therapeutic target for fibrosis.
View Full Paper
Ask AI
Bookmark
Share